Adamas pharmaceuticals stock

73 as its best level and the lowest price reached was US$7. is a specialty pharmaceutical company driven to improve the lives of those affected by chronic disorders of the central nervous system. 20, 2019 -- Adamas Pharmaceuticals, Inc. 00% from the 50-day high price and spotted a change of 43. The stock had previously closed at $7. , Jan. Adamas Pharmaceuticals stock traded up $0. The company has a quick ratio of 8. View daily, weekly or monthly format back to when Adamas Pharmaceuticals, Inc. Wednesday, April 04, 2018. 65% away from the 50-day MA while located 18. 20 with a high estimate of $40. 22, the closing trading price on August 7, 2018, Adamas Pharmaceuticals Inc (NASDAQ:ADMS) was in 17 hedge funds’ portfolios at the end of September. Why Adamas Pharmaceuticals, Inc. Change the date range, chart type and compare Adamas Pharmaceuticals, Inc. Adamas Pharmaceuticals market cap history and chart from 2013 to 2018. Today, Northland Securities reiterated its Buy rating on Adamas Pharmaceuticals Inc (NASDAQ:ADMS). (ADMS) stock price, charts, trades & the US's most popular discussion forums. Research news, charts, stock market performance and earnings. (Nasdaq: ADMS) today announced that the compensation committee of the company’s board of directors granted Real time Adamas Pharmaceuticals (ADMS) stock price quote, stock graph, news & analysis. The Company is developing its wholly-owned product candidate, ADS-5102. Adamas Pharmaceuticals (ADMS) traded moved -3. Read the news as it happens!Mar 5, 2019 Shares of Adamas Pharmaceuticals (NASDAQ:ADMS) were crashing at Mizuho and Cowen to downgrade Adamas Pharmaceuticals stock. Shares of Adamas Pharmaceuticals, Inc. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Adamas Pharmaceuticals with a $20. 16% off of the 20-day MA. Adamas Pharmaceuticals started at outperform with $31 stock price target at Leerink MarketWatch. Feb 21, 2019 An earnings beat or miss may not be the sole basis for a stock moving higher or lower. Adamas Pharmaceuticals started at outperform with $20 stock price target at Leerink MarketWatch. 4. The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price Adamas Pharmaceuticals stock opened at $7. View Adamas Pharmaceuticals income statements, balance sheet, cash flow statements, key financial ratios and more. stocksplithistory. Here's why. 7 Wall Street Stock Market & Finance report, prediction for the future: You'll find the Adamas Pharmaceuticals share forecasts, stock quote and buy / sell signals below. 5. The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price ADMS / Adamas Pharmaceuticals, Inc. 74, a current ratio of 8. 42 and a 1-year high of $32. Adamas Pharmaceuticals stock price, live market quote, shares value, historical data, intraday chart, earnings per share, dividend yield, market capitalization and news updated on Sunday, March 10, 2019. 19 million shares changed exchanged hands during trading, a drop of -757215. The company seeks to achieve this by modifying the pharmacokinetic profiles of approved drugs to create novel therapeutics for use alone and in fixed-dose combination products. View the latest ADMS stock quote and chart on MSN Money. com reports. Read the news as it happens!Adamas Pharmaceuticals Stock Price Forecast, ADMS stock price prediction. is a pharmaceutical company, which engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. and Adamas Pharmaceuticals (ADMS – Research Report) with bullish sentiments. (ADMS) stock quote, history, news and other vital information to help you with your stock trading and investing. Adamas Pharmaceuticals shares last traded at $8. is using its deep understanding of time-dependent biology to redefine the treatment experience for patients suffering from chronic neurological diseases. (NASDAQ:ADMS). Free current stock price quotes and data for Adamas Pharmaceuticals Inc (ADMS). (NASDAQ:ADMS) is currently set at 36. View Adamas Pharmaceuticals Inc. is a pharmaceutical company, which engages in discovery and development of chrono-synchronous See Company Overview Key ExecutivesView Adamas Pharmaceuticals Inc. 75 average price target, which is a 70. HC Wainwright set a $40. Other Wall Street experts have also recently posted reports on these shares. The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price Is Adamas Pharmaceuticals Inc (ADMS) A Good Stock To Buy? Insider Monkey has processed numerous 13F filings of hedge funds and famous investors to create an extensive database of hedge fund holdings. 03 during mid-day trading on Tuesday, hitting $7. You can buy this stock commission-free or purchase it within a thematic portfolio Adamas Pharmaceuticals manufactures and markets therapeutics for the treatment of neurological and infectious diseases Adamas Pharmaceuticals (ADMS) share price is $7. ADMS stock quote information – including stock price, key financials, stock charts and investing ideas containing ADMS. adamas pharmaceuticals stockFind the latest Adamas Pharmaceuticals, Inc. is a pharmaceutical company, which engages in discovery and development of chrono-synchronous See Company Overview Key Executives Latest stock price today and the US's most active stock market forums. All rights reserved. Adamas Pharmaceuticals (ADMS) share price is $7. Went bought 3,850 shares of the business’s stock in a transaction dated Wednesday, November 7th. Adamas Pharmaceuticals Inc (ADMS) SEC Filing 10-K Annual report for the fiscal year ending Sunday, December 31, 2017. Discover historical prices for ADMS stock on Yahoo Finance. (ADMS) stock from Seeking Alpha. Adamas Pharmaceuticals started at outperform with $20 stock price target at Leerink MarketWatch. Their stock Adamis Pharmaceuticals Corporation is a specialty biopharmaceutical company focused on developing and commercializing pharmaceutical products in the therapeutic areas of respiratory disease and allergy. Wall Street analysts on the sell-side covering shares of Adamas Pharmaceuticals, Inc. There are 3 Hold Ratings, 3 Buy Ratings, 1 Sell Ratings, no Strong Buy Ratings on Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) tinted loss of -0. 1% upside from current levels. Real time Adamas Pharmaceuticals (ADMS) stock price quote, stock graph, news & analysis. 56, one of the worst stocks on the Nasdaq on early trading. com provides: stock quote, technical analysis, fundamental analysis, stock rating, stock news 05 Mar 2019 20:09:18 Z Why Adamas Pharmaceuticals Shares Adamas Pharmaceuticals, Inc. 00 price target on Adamas Pharmaceuticals and gave the stock a “buy” rating in a research report on Monday, January 14th. (Nasdaq: ADMS) today announced that the company will report fourth quarter and year-end 2018 financial results. Adamas Pharmaceuticals has a 1-year low of $7. 24. Adamas Pharmaceuticals, Inc. 70 million, a PE ratio of -1. Stock Continued to Slide in November - The Motley Fool www. View Adamas Pharmaceuticals Inc. (NASDAQ:ADMS) tinted loss of -1. Market data is Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) is a huge mover today! The stock decreased 2. 41. 62% away from the 50-day MA and 1. The firm has a market cap of $303. Adamas Pharmaceuticals Inc. A low number indicates a Buy and a higher number a Sell. 96% distance from the 200-day MA and stock price situated 28. View detailed financial information, real-time news, videos, quotes and analysis on Adamas Pharmaceuticals Inc. 38 Million shares. See if the stock goes on to build a promising consolidation that could kick off a new price move. (NASDAQ:ADMS) has been utilizing an ROE that is roughly -101. Income refers to interest payments from fixed-income ETFs and dividend payments from stock-based ETFs. Summary quote, performance, and fundamental analysis for NASDAQ:ADMS Adamas Pharmaceuticals, Inc. 2/27/2019 · Adamas Pharmaceuticals, Inc. Find real-time ADMS - Adamas Pharmaceuticals Inc stock quotes, company profile, news and forecasts from CNN Business. 46% to closing price of $11. (ADMS) stock price and volume charts for most recent trading day, 5-day, 1-month and longer monthly and yearly timeframes. Stock Quotes. Cowen set a $30. The Company is engaged in developing medicines to manage the daily lives of those affected by chronic Adamas Pharmaceuticals, Inc. 57% distance from the 200-day MA and stock price situated 18. Please continue to support Morningstar by turning Adamas Pharmaceuticals Inc is a pharmaceutical company focused on the development and commercialization of therapeutics targeting chronic disorders of the central nervous systems. ADS-0021 08/17 Real time Adamas Pharmaceuticals (ADMS) stock price quote, stock graph, news & analysis. ’s …Adamas Pharmaceuticals (ADMS) Lowered to “Sell” at Zacks Investment Research Thursday, February 28, 2019 04:09 PM Zacks Investment Research downgraded shares of Adamas Pharmaceuticals (NASDAQ:ADMS) from a hold rating to a sell rating in a research report …Adamas Pharmaceuticals, Inc. News Headlines for Adamas Pharmaceuticals Inc. One analyst has rated the stock with a sell rating, four have assigned a hold rating and seven have given a …Intraday chart for ADAMAS PHARMACEUTICALS INC Daily chart ADAMAS PHARMACEUTICALS INC Duration : Auto. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Price based on past earnings Are Adamas Pharmaceuticals's earnings available for a low price, and how does this compare to other companies in the same industry?Adamas Pharmaceuticals Inc. Dec 11, 2018 Adamas Pharmaceuticals' valuation took yet another hit last month. The brokerage currently has a “buy” rating on the specialty pharmaceutical company’s stock. 08:02 AM ET We get why people use ad blockers … … but ads help us provide you with high-quality content at no cost to you. The Company is engaged in developing medicines to manage the daily lives of those affected by chronic neurologic disorders. 62, but opened at $8. Adamas Pharmaceuticals holds a buysignal from the short-term moving average; at the same time, however, a sales signal from the long-term average. Adamas Pharmaceuticals (NASDAQ:ADMS) last posted its earnings results on Monday, March 4th. 00 price target on shares of Adamas Pharmaceuticals and gave the stock a buy rating in a report on Monday, January 14th. 25 and last traded at $11. 83M and relative volume of 0. (NASDAQ:ADMS), with 3 analysts believing it is a strong buy. Here are some recent quotes from research analysts about Adamas Pharmaceuticals stock: 1. Check out our ADMS stock analysis, current ADMS quote, charts, and historical prices for Adamas Pharma stock. The stock is $-76. Find the latest Adamas Pharmaceuticals, Inc. is a pharmaceutical company. was founded in 2000 and is headquartered in Emeryville, California. operates as a specialty pharmaceutical company that focuses on the development and commercialization of therapeutics targeting chronic disorders of the central nervous systems. According to present data Adamas Pharmaceuticals's ADMS shares and potentially its market environment have been in bearish cycle last 12 months (if exists). 00 target price on Adamas Pharmaceuticals and gave the stock a buy rating in a research note on Monday, January 14th. 001 share price. (NASDAQ:ADMS) recorded -29. 8 Wall Street analysts have issued ratings and price targets for Adamas Pharmaceuticals in the last 12 months. DOW JONES, A NEWS CORP COMPANY. 62, but opened at $8. 9 in recent trading session. 74 and a current ratio of 8. 00. The stock has a market capitalization of $303. 08:02 AM ET. is a pharmaceutical company, which engages in discovery and development of chrono-synchronous See Company Overview Key ExecutivesInvestors tracking shares of Adamas Pharmaceuticals (ADMS) may be focusing on where the stock is trading relative to its 52-week high and low. 00 price target on shares of Adamas Pharmaceuticals and gave the stock a “buy” rating in …stoxline. ”. 09% away from the 50-day MA while located 18. According to various rumors a takeover could Adamas Pharmaceuticals, Inc. Tracking current stock price levels in relation to some other popular moving averages, we have noted that the stock is trading -1. operates as a specialty pharmaceutical company. ROA shows that how profitable a company is relative to its total assets. Our vision is grand, our goal bold: to create and commercialize a new generation of medicines intended to lessen the burden of disease on patients, caregivers and society. Zacks Investment Research downgraded shares of Adamas Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, February 27th. Get Adamas Pharmaceuticals Inc (ADMS:NASDAQ) real-time stock quotes, news and financial information from CNBC. 25. Market capitalization (or market value) is the most commonly used method of measuring the size of a publicly traded company and is calculated by multiplying the current stock price by the number of diluted shares outstanding. Whereas 3 of them predict the stock is a hold. (ADMS) Analyst Guide Several analysts have released their opinion on Adamas Pharmaceuticals, Inc. Adamas Pharmaceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $29. Since the longterm average is above the short-term average there is a general sales signal in the stock. Corporate governance Adamas Pharmaceuticals, Inc. 72% or $0. / INTEGRATED CORE STRATEGIES (US) LLC (Passive Investment) 2019-03-01 sec. Includes settings for advanced statistics, like moving average and relative strength index. 54% to closing price of $16. Dive deeper with interactive charts and top stories of Adamas Pharmaceuticals Inc. 01. com reports. 88. stock price, stock quotes and financial overviews from MarketWatch. 01. View detailed financial information, real-time news, videos, quotes and analysis on Adamas Pharmaceuticals Inc. The ADS-5102 is a treatment for levodopa-induced dyskinesia in patients View detailed financial information, real-time news, videos, quotes and analysis on Adamas Pharmaceuticals Inc. . Menu. Adamas Pharmaceuticals Inc (ADMS) stock quote, charts, historical data, financials. Stock Continued to Slide in November -- The Motley Fool View the basic ADMS stock chart on Yahoo Finance. …Read ADMS related news and find out why Adamas Pharmaceuticals’s (ADMS) news sentiment is more negative in relation to stocks in the Healthcare sector. 00, with a volume of 37997 shares changing hands. Adamas Pharmaceuticals, Inc. DOW JONES, A NEWS CORP COMPANY News Corp is a network of leading companies in the worlds of diversified media, news, education, and information services. Adamas Pharmaceuticals (NASDAQ:ADMS) received a $40. (NASDAQ:ADMS)’s earnings per share has been growing at a -41. 09:51 AM ET. © 2019 Adamas Pharmaceuticals, Inc. The Distribution Yield is the trailing 12-Month End Yield derived by adding the trailing 12-month's income distributions and dividing the total by the last month's ending share price. 1 m and the revenue was $34. In other Adamas Pharmaceuticals news, CEO Gregory T. 001 share price. fool. The stock Rating process is purely mechanical. Dec 11, 2018 Adamas Pharmaceuticals' valuation took yet another hit last month. Adamas Pharmaceuticals is not currently offering a proper buying opportunity. 76 (down 1. The latest Adamas Pharmaceuticals Inc USD0. 05 March 2019 Why Adamas Pharmaceuticals Shares Are Crashing Today 05 March 2019 The Daily Biotech Pulse: Novartis Psoriasis Drug Found Superior, Ascendis Offering, Adamas Earnings 04 March 2019 Adamas Pharmaceuticals Inc (ADMS) Q4 2018 Earnings Conference Call TranscriptAdamas Pharmaceuticals, Inc. Adamas Pharmaceuticals Inc is a pharmaceutical company focused on the development and commercialization of therapeutics targeting chronic disorders of the central nervous systems. ADS-0021 08/17Adamas Pharmaceuticals, Inc. Adamas Pharmaceuticals' valuation took yet another hit last month. 5 percent rate over the past 5 year when average revenue increase was noted as -56. , Feb. or its related companies. Shares of ADMS opened at $7. Get detailed information about the Adamas Pharma (ADMS) stock including price, charts, technical analysis, historical data, Adamas Pharmaceuticals Inc reports Stock analysis for Adamas Pharmaceuticals Inc (ADMS:NASDAQ GM) including stock price, stock chart, company news, key statistics, fundamentals and Find the latest Adamas Pharmaceuticals, Inc. At Adamas, we know that our employees are the driving force behind the company’s success. comStock quote for Adamas Pharmaceuticals, Inc. 09 Adamas Pharmaceuticals Inc (NASDAQ:ADMS) stock is down sharply this morning -- last seen off 29. 06 and a beta of 1. 56, one of the worst stocks on Adamas Pharmaceuticals, Inc. Explore commentary on Feb 21, 2019 An earnings beat or miss may not be the sole basis for a stock moving higher or lower. 10, 2019 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. Find out the latest news headlines for Adamas Pharmaceuticals, Inc. Free forex prices, toplists, indices and lots more. This is based on a numerical chart where each stock recommendation (Buy,Sell,Hold) is translated into a numerical equivalent. Approximately 640,050 shares were traded during mid-day trading, an increase of 36% from the average daily volume of 469,766 shares. 9% per year, following the -29% drop that was witnessed during the past five years. Weighing on the shares is The amount the stock market is willing to pay for Adamas Pharmaceuticals's earnings, growth and assets is considered below, and whether this is a fair price. Adamas Pharmaceuticals Inc (NASDAQ:ADMS) stock is down sharply this morning -- last seen off 29. Stock - ADMS news, historical stock charts, analyst ratings, financials, and today’s Adamas Pharmaceuticals Inc. Why Adamas Pharmaceuticals, Inc. 16 on Tuesday. EPS ratio determined by looking at last 12 month figures is -5. and changed its name to Adamas Pharmaceuticals, Inc. 21 during the last trading session, reaching $7. 00 price target on the specialty pharmaceutical company’s stock. News for Adamas Pharmaceuticals Inc. 2857, suggesting that the stock has a possible upside of 195. (ADMS), including valuation measures, fiscal year financial statistics, trading records, share statistics and more. The volume of 0. against other companies. Adamas Pharmaceuticals (ADMS): Adamas Pharmaceuticals (ADMS) stock has been separated -54. Weighing on the shares is Shares of Adamas Pharmaceuticals stock opened at $7. 9 in recent trading session. The script traded as low as $11. 8% upside from current levels. 42 and a one year high of $32. At the time of writing, the stock had recently reached at …Latest stock price today and the US's most active stock market forums. (NASDAQ: ADMS) Adamas Pharmaceuticals, Inc. gov - 1 SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. The Stock has market cap of $241. Friday, November 16, 2018. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. Adamas Pharmaceuticals (ADMS) Stock’s Ratio Analysis: The Company was able to keep Return on assets (ROA) at -49. One analyst has rated the stock with a sell recommendation, four have given a hold recommendation and seven have issued a buy recommendation on the company. (the “Company”). 09% (-0. ADMS / Adamas Pharmaceuticals, Inc. Adamas Pharmaceuticals (NASDAQ:ADMS) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Monday. 1. Adamas Pharmaceuticals is registered under the ticker NASDAQ:ADMS . 09% (-0. Please continue to support Morningstar by turning Adamas Pharmaceuticals Inc (NASDAQ:ADMS) has received an average recommendation of “Hold” from the twelve research firms that are covering the stock, Marketbeat. Adamas Pharmaceuticals, Inc Stock Market info Recommendations: Buy or sell Adamas Pharmaceuticals stock? Wall Street Stock Market & Finance report, prediction for the future: You'll find the Adamas Pharmaceuticals share forecasts, stock quote and buy / sell signals below. (ADMS) - free report >> Mar 5, 2019 Adamas Pharmaceuticals Inc (NASDAQ:ADMS) stock is down sharply this morning -- last seen off 29. 16 on Wednesday. 01 points) to US$11. About Adamas. 5%, with stock analysts predicting that the company’s EPS for the next five years will go up by 17. is a pharmaceutical company, which engages in discovery and development of chrono-synchronous See Company Overview Key Executives Profile Adamas Pharmaceuticals MORE. focuses on the development and commercialization of therapeutics for chronic disorders of the central nervous systems (CNS) in the United States. 13 points) to US$8. 50, a 148. 94% loss during trading session on November 2nd, 2018. operates as a specialty pharmaceutical company that focuses on the development and commercialization of therapeutics targeting chronic disorders of …3/19/2019 · Adamas Pharmaceuticals, Inc. Latest Breaking news and Headlines on Adamas Pharmaceuticals, Inc. Price based on past earnings Are Adamas Pharmaceuticals's earnings available for a low price, and how does this compare to other companies in the same industry? See ADMS stock predictions by 2 financial experts and find out if their Adamas Pharmaceuticals stock forecast (ADMS) is more bullish in comparison to other stocks in the Healthcare sector. 47% (-0. 17 Million shares climbed down over an trading activity of 530. at NASDAQ. 75 average price target, which is a 70. There are 3 Hold Ratings, …Adamas Pharmaceuticals Inc discovers, develops, and sells therapies for chronic neurologic disorders. 90. com/?symbol=ADMSAdamas Pharmaceuticals (ADMS) has 2 splits in our Adamas Pharmaceuticals stock split history database. This was a 3 for 2 split, meaning for each 2 shares of ADMS owned pre-split, the shareholder now owned 3 shares. Adamas Pharmaceuticals (ADMS) has 2 splits in our Adamas Pharmaceuticals stock split history database. 5 Mar 2019 Shares of Adamas Pharmaceuticals (NASDAQ:ADMS) were crashing at Mizuho and Cowen to downgrade Adamas Pharmaceuticals stock. Adamas Pharmaceuticals Inc (NASDAQ:ADMS) has been given a consensus rating of “Buy” by the twelve brokerages that are covering the stock, MarketBeat Ratings reports. 03% from the 50-day low point. This has been announced in a research report issued to clients and investors on 5 March. operates as a specialty pharmaceutical company. GOCOVRI is the company’s drug treatment of dyskinesia in patients with Parkinson’s disease. The Company is developing its lead wholly owned product candidate, ADS-5102, for a complication of Parkinson's disease known as levodopa induced dyskinesia (LID), and as a treatment for chronic behavioral symptoms associated with traumatic brain injury (TBI). 3M in Q4 and ~$34M for 2018. 26% off of the 20-day MA. The ADS-5102 is a treatment for levodopa-induced dyskinesia in patients with Parkinson's disease. adamas pharmaceuticals (adms) - develops therapeutic products for the treatment of chronic disorders of the central nervous system. The common stock is listed on the NASDAQ Global Market under the symbol “ADMS. Explore commentary on Adamas Pharmaceuticals Inc. ’s ISS …The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Adamas Pharmaceuticals with a $20. The price target of Adamas Pharmaceuticals, Inc. (ADMS). They presently have a $11. 16. The Company develops drugs to improve the lives of those affected by chronic disorders of the central nervous system Adamas Pharmaceuticals, Inc. 76 on Tuesday. The company has a market capitalization of $303. 95 and a debt-to-equity ratio of 1. At Adamas Pharmaceuticals, Inc. At Adamas Pharmaceuticals, Inc. About Adamas Pharmaceuticals Inc Adamas Pharmaceuticals, Inc. and hear what the Get Adamas Pharmaceuticals Inc (ADMS:NASDAQ) real-time stock quotes, news and financial information from CNBC. Stock Continued to Slide in November -- The Motley FoolEMERYVILLE, Calif. . 5% at $8. One analyst has rated the stock with a sell recommendation, four have assigned a hold recommendation and seven have given a buy recommendation to the company. IPO & Stock Price . Two research The Distribution Yield is the trailing 12-Month End Yield derived by adding the trailing 12-month's income distributions and dividing the total by the last month's ending share price. 5% at $8. © 2019 Adamas Pharmaceuticals, Inc. ’s …Adamas Pharmaceuticals (ADMS) Lowered to “Sell” at Zacks Investment Research Thursday, February 28, 2019 04:09 PM Zacks Investment Research downgraded shares of Adamas Pharmaceuticals (NASDAQ:ADMS) from a hold rating to a sell rating in a research report …Adamas Pharmaceuticals Inc (NASDAQ:ADMS) has earned a consensus recommendation of “Buy” from the twelve research firms that are covering the stock, MarketBeat. Latest Breaking news and Headlines on Adamas Pharmaceuticals, Inc. adamas pharmaceuticals stock Please continue to support Morningstar by turning Adamas Pharmaceuticals, Inc. 89. Adamas Pharmaceuticals (ADMS) stock Trading Summary: Adamas Pharmaceuticals (ADMS) stock changed position at 2. According to Zacks Investment Research, "Adamas Pharmaceuticals, Inc. C. Adamas Pharmaceuticals (ADMS) stock Trading Summary: Adamas Pharmaceuticals (ADMS) stock changed position at -8. The stock has a consensus rating of Hold Adamas Pharmaceuticals Inc is a pharmaceutical company focused on the development and commercialization of therapeutics targeting chronic disorders of the central nervous systems. The stock has a history of bouncing out of the oversold territory The shares of Adamas Pharmaceuticals rallied 40% on Friday after FDA approval of its key drug candidate. Today, Adamas Pharmaceuticals Inc (NASDAQ:ADMS) stock was downgraded by Needham & Company LLC from Buy to Hold. 56, one of the worst stocks on the Nasdaq on early trading. The company was formerly known as NeuroMolecular Pharmaceuticals, Inc. ADMS's price target is $22. The latest Adamas Pharmaceuticals Inc USD0. 96 and a beta of 1. Zacks Investment Research downgraded shares of Adamas Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Monday, October 8th. Common Stock Common Stock (ADMS) with real-time last sale and extended hours stock prices, company news, charts, and research at Nasdaq. Davis Polk advised the joint book-running managers in connection with a $124. Mizuho’s price objective would suggest a potential upside of 20. 95. 27% off of the 20-day MA. 3/8/2019 · View the latest ADMS stock quote and chart on MSN Money. 4 Million shares climbed down over an trading activity of 682. (NASDAQ:ADMS) have a mean recommendation of 2. Its products includes ADS-5012, ADS-4101, and Namenda XR. 00, with a volume of 37997 shares changing hands. 58. The stock traded as high as $11. engages in the development and commercialization of controlled release combination therapeutics to treat healthcare problems, primarily in the areas of infectious diseases and central nervous system disorders. We get why people use ad blockers … … but ads help us provide you with high-quality content at no cost to you. 5%, with stock analysts predicting that the company’s EPS for the next five years will go up by 17. Adamas stock rises 5% on strong launch of Parkinson's drug MarketWatch. The last closing price represents the price at which the last trade occurred. also maintained a Buy rating on the stock with a $30 price target. stock price. stock was issued. (Nasdaq: ADMS) today announced that the compensation committee of the company’s board of directors granted four new employees the option to purchase an aggregate of 35,366 shares of the company’s common stock…Adamas Pharmaceuticals, Inc. Adamas Pharmaceuticals presently has a consensus rating of “Hold” and a consensus target price of $23. 00 price objective on shares of Adamas Pharmaceuticals and gave the stock a “buy” rating in a …Get all the key statistics for Adamas Pharmaceuticals, Inc. News & Events; Adamas scientists confirmed this time-dependent effect through in vivo modeling and preclinical experiments, Ideal candidate will have experience in specialty pharmaceuticals, with a background in Parkinson’s See ADMS stock predictions by 2 financial experts and find out if their Adamas Pharmaceuticals stock forecast (ADMS) is more bullish in comparison to other stocks in the Healthcare sector. 97 in recent trading session. is a clinical-stage specialty pharmaceutical company. 70 million, a PE ratio of -2. and hear what the Adamas Pharmaceuticals, Inc. Adamas Pharmaceuticals market cap is $212. adamas pharmaceuticals (adms) - develops therapeutic products for the treatment of chronic disorders of the central nervous system. Adamas Pharmaceuticals Inc (NASDAQ:ADMS) is a micro-cap stock that has started to engage some major eyeballs among traders and investors focused on new growth potential in the biopharma space after the stock went into orbit to close out last week. 4%). 3/14/2019 · ValuEngine lowered Adamas Pharmaceuticals from a hold rating to a sell rating in a research note on Monday, February 4th. 7 and last traded at $11. Stock Continued to …We are generating a pipeline of innovative treatmens for chronic neurologic disorders. Adamas Pharmaceuticals develops innovative treatments for chronic neurologic disorders. The stock decreased 2. The Company offers a platform based on an understanding of time dependent biologic effects Adamas Pharmaceuticals, Inc. 00 on the shares. Shares of Adamas Pharmaceuticals stock opened at $8. According to various rumors a takeover could See ADMS price target based on 7 analysts offering 12 month price targets for Adamas Pharmaceuticals (ADMS) in the last 3 months. 46% to closing price of $11. 16. ’s ISS governance QualityScore as of 28 February Adamas Pharmaceuticals, Inc. is a pharmaceutical company, which engages in discovery and development of chrono-synchronous See Company Overview Key Executives Today, Adamas Pharmaceuticals Inc (NASDAQ:ADMS) stock was downgraded by Needham & Company LLC from Buy to Hold. Shares of Adamas Pharmaceuticals Inc (NASDAQ:ADMS) gapped down prior to trading on Wednesday . Read the news as it happens! Mar 5, 2019 Shares of Adamas Pharmaceuticals (NASDAQ:ADMS) were crashing at Mizuho and Cowen to downgrade Adamas Pharmaceuticals stock. Corporate Governance Adamas Pharmaceuticals, Inc. Adamas Pharmaceuticals Inc is primarily focused on the development and commercialization of therapeutics targeting chronic disorders of the central nervous systems. Wall Street Stock Market & Finance report, prediction for the future: You'll find the Adamas Pharmaceuticals share forecasts, stock quote and buy / sell signals below. 10% in the trailing twelve month. 06% away from the 200-day MA. The company's approved/commercial product is GOC3/15/2019 · Adamas Pharmaceuticals, Inc. That’s why we offer a comprehensive compensation and benefits program that includes generous stock option and RSU grants and the following: First Week Of February 2019 Options Trading For Adamas Pharmaceuticals (ADMS) Investors in Adamas Pharmaceuticals Inc saw new options begin trading this week, for the February 2019 expiration. Adamas Pharmaceuticals has a one year low of $7. Adamas Pharmaceuticals started at outperform with $20 stock price target at Leerink MarketWatch Adamas Pharmaceuticals Inc (NASDAQ: ADMS) is having an interesting start to the trading session this morning as rumors break surrounding the company. , we seek to redefine the treatment experience for patients suffering from chronic neurological diseases. 41. Over the same time span, the stock marked US$41. 42. The company has a debt-to-equity ratio of 1. 08:02 AM ET Adamas Pharmaceuticals (ADMS) negotiated the trading capacity of 283630 shares and observing the average volume of last three months the stock traded 562. The corporation has a market cap of US$229. View the basic ADMS stock chart on Yahoo Finance. 56, one of the worst stocks on Adamas Pharmaceuticals Inc. EMERYVILLE, Calif. About Adamas Pharmaceuticals Inc. Adamas Pharmaceuticals Inc. 01, a quick ratio of 8. The stock rating of Adamas Pharmaceuticals (NASDAQ:ADMS) was lowered by stock analysts at Cowen & Co. (NASDAQ:ADMS)’s stock as a Neutral in a research note published on Monday, November 5th, 2018. 77 on Thursday. Please note that all recommendations are based on our model's results and do not represent our personal opinion. 58K shares. Adamas Pharmaceuticals Inc discovers, develops, and sells therapies for chronic neurologic disorders. to a Hold. , we seek to redefine the treatment experience for patients suffering from chronic neurological diseases. 9% per year, following the -29% drop that was witnessed during the past five years. ADAMAS PHARMACEUTICALS: Announces Closing of Its Public Offering of Common Stoc. Concluded 2017 with $176. Adamas Pharmaceuticals (ADMS) stock positioned -34. The company's approved/commercial product is GOCOVRI, an amantadine therapy for the treatment of levodopa-induced dyskinesia in patients with Parkinson's disease. 3M in Q4 and ~$34M for 2018. Disclaimer. The shares of Adamas Pharmaceuticals rallied 40% on Friday after FDA approval of its key drug candidate. (ADMS), a pharmaceutical company yesterday announced that the Food and Drug Administration (FDA) has approved GOCOVRI. Mizuho rated the Adamas Pharmaceuticals, Inc. The shares were purchased at an average price of $12. in July 2007. promising and undervalued biopharma stock were up some 40% in trading on Friday Adamas Pharmaceuticals announced its Q4 and 2018 earnings and reported GOCOVRI sales to be ~$13. (ADMS) today announced that the compensation committee of the company’s board of directors granted four new employees the option to purchase an aggregate of 44,016 shares of the company’s common stock, at a per share exercise price of $24. 98 per share, for a total transaction of $49,973. Monday, March 12, 2018. 57%. Adamas to Announce Fourth Quarter and Year-End 2018 Financial Results and Host Conference Call on March 4, 2019. Adamas Pharmaceuticals develops innovative treatments for chronic neurologic disorders. Adamas Pharmaceuticals' valuation took yet another hit last month. 19% from the 50-day high price and spotted a change of 59. 5 million SEC-registered follow-on offering of 3,000,000 shares of common stock of Adamas Pharmaceuticals, Inc. The best long-term & short-term Adamas Pharmaceuticals share price prognosis Adamas Pharmaceuticals develops innovative treatments for chronic neurologic disorders. 00 price objective on shares of Adamas Pharmaceuticals and gave the company a buy rating in a report on Thursday, November 1st. ADMS investors should be aware of a decrease in hedge fund interest recently. focuses on the discovery, development, and commercialization of medicines for patients suffering from chronic neurologic disorders. stoxline. (ADMS) - free report >> Mar 5, 2019 Adamas Pharmaceuticals Inc (NASDAQ:ADMS) stock is down sharply this morning -- last seen off 29. Real time Adamas Pharmaceuticals (ADMS) stock price quote, stock graph, news & analysis. , March 12, 2019 -- Adamas Pharmaceuticals, Inc. is a pharmaceutical company, which engages in discovery and development of chrono-synchronous See Company Overview Key Executives ValuEngine lowered Adamas Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Monday, February 4th. Adamas Pharmaceuticals (ADMS) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release The earnings report might help the stock move higher if these key numbers are better than Adamas Pharmaceuticals, Inc. Adamas Pharmaceuticals (ADMS) stock positioned -43. Adamas Pharmaceuticals Inc is primarily focused on the development and commercialization of therapeutics targeting chronic disorders of the central nervous systems. 01 points) to US$11. 00 price target on shares of Adamas Pharmaceuticals and gave the stock a “buy” rating in a research report on Thursday, November 1st. EMERYVILLE, Calif. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max. In a report issued on November 1, Cowen & Co. Get Adamas Pharmaceuticals Inc (ADMS:NASDAQ) real-time stock quotes, news and financial information from CNBC. Adamas Pharmaceuticals (NASDAQ:ADMS)‘s stock had its “hold” rating reaffirmed by stock analysts at Mizuho in a report issued on Friday. 35% from the company’s previous close. Adamas Pharmaceuticals Inc (NASDAQ:ADMS) shares gapped down before the market opened on Wednesday . ADMS: Get the latest Adamas Pharmaceuticals stock price and detailed information including ADMS news, historical charts and realtime prices. Adamas Pharmaceuticals stock opened at $8. 32K shares. We get why people use ad blockers … … but ads help us provide you with high-quality content at no cost to you. discovers, develops, and sells therapies for chronic neurologic disorders. promising and undervalued biopharma stock were up some 40% in trading on Friday Adamas Pharmaceuticals, Inc. Friday, Nov 16, 2018. 00 and a low estimate of $5. 05 m in FY, 2018. The stock of Adamas Pharmaceuticals, Inc. 2 by the analysts. Adamas Pharmaceuticals Inc (ADMS) stock quote, charts, historical data, financials. 65% from the 30-day average session volume of 553. News Corp is a network of leading companies in the worlds of diversified media, news, education, and information services. Find real-time ADMS - Adamas Pharmaceuticals Inc stock quotes, company profile, news and forecasts from CNN Business. The stock has a history of bouncing out …The amount the stock market is willing to pay for Adamas Pharmaceuticals's earnings, growth and assets is considered below, and whether this is a fair price. (NASDAQ:ADMS) Adamas Pharmaceuticals, Inc. , incorporated on November 15, 2000, is a pharmaceutical company. (ADMS) Stock Chart - Get stock charts for Adamas Pharmaceuticals, Inc. (ADMS) stock price, charts, trades & the US's most popular discussion forums. 12/24/2015 · Adamas Pharmaceuticals Inc - ADMS Stock Chart Technical Analysis for 12-24-15 Free Guide - The 5 Tools I Use To Find Stocks To Trade: https://claytrader. The company's approved/commercial product is GOCOVRI, an amantadine therapy for the treatment o Adamas Pharmaceuticals holds sales signals from both short- and long-term moving averages. 17 Million shares climbed down over …Adamas Pharmaceuticals, Inc. is a pharmaceutical company, which engages in discovery and development of chrono-synchronous See Company Overview Key Executives Shares of Adamas Pharmaceuticals Inc (NASDAQ:ADMS) have earned a consensus recommendation of “Buy” from the twelve ratings firms that are presently covering the company, MarketBeat. Join the Nasdaq Community today and get free, instant access to portfolios, stock ratings, real-time alerts, and more! Stock quote for Adamas Pharmaceuticals, Inc. 74, a current ratio of 8. Adamas Pharmaceuticals announced its Q4 and 2018 earnings and reported GOCOVRI sales to be ~$13. com provides: stock quote, technical analysis, fundamental analysis, stock rating, stock news 05 Mar 2019 20:09:18 Z Why Adamas Pharmaceuticals Shares Free current stock price quotes and data for Adamas Pharmaceuticals Inc (ADMS). The Company develops drugs to improve the lives of those affected by chronic disorders of the central nervous system. 96 and a beta of 1. 00 price objective from equities researchers at HC Wainwright in a report released on Monday. 25. 90. First Week Of February 2019 Options Trading For Adamas Pharmaceuticals (ADMS) Investors in Adamas Pharmaceuticals Inc saw new options begin trading this …Adamas Pharmaceuticals Inc. Adamas Pharmaceuticals Inc (NASDAQ: ADMS) is having an interesting start to the trading session this morning as rumors break surrounding the company. The first split for ADMS took place on February 16, 1999. 38 Below its 1-Year High which is $32. According to Zacks, “Adamas Pharmaceuticals, Inc. There are 4 Buy Ratings, 3 Hold Ratings, 1 Sell Ratings, no Strong Buy Ratings on the stock. The company's approved/commercial product is GOCOVRI, an amantadine therapy for the treatment oAdamas Pharmaceuticals, Inc. 31 Million shares. 77 on Tuesday. 4 million in cash and investments, which includes $65 million in funding from HealthCare Royalty Partners in the fourth quarter of 2017, as part of the $100 million royalty-backed debt agreement executed in May 2017. Adamas Pharmaceuticals (ADMS) traded moved 0. Their average twelve-month price target is $22. com provides: stock quote, technical analysis, fundamental analysis, stock rating, stock newsAdamas Pharmaceuticals, Inc. Adamas Pharmaceuticals (ADMS) stock changed position at -8. 2% during mid-day trading on Wednesday . 94% from the 50-day low point. 8% upside from current levels. ’s ISS Governance QualityScore as of March 1, 2019 is 7. Here's why. Full Description. Adamas Pharmaceuticals Inc (NASDAQ:ADMS) shares gapped down before the market opened on Wednesday . Adamas Pharmaceuticals (ADMS) Rating Increased to Hold at BidaskClub Thursday, February 28, 2019 06:10 AM BidaskClub upgraded shares of Adamas Pharmaceuticals (NASDAQ:ADMS) from a sell rating to a hold rating in a research report released on Monday morning. (ADMS) 4x Upside for a Misunderstood Drug Maker Disclaimer: As of the publication date of this report, Kerrisdale Capital Management, LLC and its affiliates (collectively, “Kerrisdale”), have long positions in the stock of Adamas Pharmaceuticals, Inc. The company had a trading volume of 74,926 shares, compared to its average volume of 640,491. 70 million, a P/E ratio of -1. In addition, there is a general sales signal from the relation between the two signals where the long-term average is above the short-term average. , incorporated on November 15, 2000, is a pharmaceutical company. BidaskClub upgraded shares of Adamas Pharmaceuticals (NASDAQ:ADMS) from a sell rating to a hold rating in a research report released on Monday morning. 95 and a debt-to-equity ratio of 1. 97 Million. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 ADAMAS PHARMACEUTICALS, INC. com - December 12 at 5:03 PM Why Adamas Pharmaceuticals, Inc. com/lp/Free Tác giả: ClayTraderLượt xem: 254Adamas Pharmaceuticals Stock Split Historyhttps://www. Adamas Pharmaceuticals Inc was incorporated in the State of Delaware on November 15, 2000. Adamas Pharmaceuticals Inc (NASDAQ:ADMS) shares were up 5